Loading…

Comparison of different pharmacodynamic models for PK–PD modeling of verapamil in renovascular hypertension

The aim of this work was to compare the suitability of different pharmacodynamic models for PK–PD modeling of verapamil cardiovascular effects in aortic coarctated rats (ACo), a model of renovascular hypertension. A “shunt” microdialysis probe was inserted in a carotid artery of anaesthetized sham-o...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmacological and toxicological methods 2008-05, Vol.57 (3), p.212-219
Main Authors: Bertera, Facundo M., Mayer, Marcos A., Opezzo, Javier A.W., Taira, Carlos A., Höcht, Christian
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3482-1a15a7e84237bd45745e3e360d95cbc8c23ccb4a67ed7246a91e9d393298c4aa3
cites cdi_FETCH-LOGICAL-c3482-1a15a7e84237bd45745e3e360d95cbc8c23ccb4a67ed7246a91e9d393298c4aa3
container_end_page 219
container_issue 3
container_start_page 212
container_title Journal of pharmacological and toxicological methods
container_volume 57
creator Bertera, Facundo M.
Mayer, Marcos A.
Opezzo, Javier A.W.
Taira, Carlos A.
Höcht, Christian
description The aim of this work was to compare the suitability of different pharmacodynamic models for PK–PD modeling of verapamil cardiovascular effects in aortic coarctated rats (ACo), a model of renovascular hypertension. A “shunt” microdialysis probe was inserted in a carotid artery of anaesthetized sham-operated (SO) and ACo rats for determination of verapamil plasma concentrations and their effects on blood pressure and heart rate after intravenous application (1 and 3 mg kg − 1 ). Correlation between verapamil plasma levels and their cardiovascular effects was established by fitting data to a linear, and a conventional and modified E max model. No differences in verapamil volume of distribution were observed between experimental groups. Whilst clearance increased with dose in SO rats, no differences were found in verapamil clearance in ACo comparing both dose levels. A good correlation between verapamil plasma unbound concentrations and their hypotensive and chronotropic effects was found in both experimental groups using the tested PK–PD models. Although all pharmacodynamic models allowed a precise estimation of verapamil PK–PD parameters, linear and E max model did not permit an accurate PK–PD parameter estimation for the hypotensive and chronotropic effect, respectively. Conversely, the modified E max model allows both a precise and accurate estimation of PK–PD parameters for verapamil effects. Although, absolute verapamil blood pressure lowering effect was greater in ACo rats compared with SO rats, no differences were found in verapamil PK–PD parameters estimated for the hypotensive response. Side-by-side comparison of the tested pharmacodynamic models showed that accuracy of PK–PD parameters estimation by using the linear and classical E max model depends on the magnitude of concentration–effect curve covered in the study. Conversely, the modified E max model allowed both a precise and accurate estimation of PK–PD parameters, suggesting that the modified E max pharmacodynamic model is the most suitable for verapamil PK–PD modeling.
doi_str_mv 10.1016/j.vascn.2008.03.002
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71632824</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1056871908000233</els_id><sourcerecordid>19609043</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3482-1a15a7e84237bd45745e3e360d95cbc8c23ccb4a67ed7246a91e9d393298c4aa3</originalsourceid><addsrcrecordid>eNqFkU1uFDEQha0IRH7ICSIhr9h1U_7pbnuRBRpIQEQiC5Cyszx2NfGo227smZFmxx24ISdJDzNSdrCqUul7r0r1CLliUDNg7btVvbXFxZoDqBpEDcBPyBlTnaikUg8v5h6atlId06fkvJQVAAjN5CtyypSUXAs4I-MijZPNoaRIU0996HvMGNd0erR5tC75XbRjcHRMHodC-5Tp_Zc_v37ffziMQvyxF24x22kGBxoinQ3S_rbNYDN93E2Y1xhLSPE1ednboeDlsV6Q7zcfvy0-VXdfbz8v3t9VTkjFK2ZZYztUkotu6WXTyQYFiha8btzSKceFc0tp2w59x2VrNUPthRZcKyetFRfk7cF3yunnBsvajKE4HAYbMW2K6VgruOLyvyDTLWiQYgbFAXQ5lZKxN1MOo807w8Ds4zAr8zcOs4_DgDBzHLPqzdF-sxzRP2uO_5-B6wMw_xa3AbMpLmB06ENGtzY-hX8ueAKWip8w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19609043</pqid></control><display><type>article</type><title>Comparison of different pharmacodynamic models for PK–PD modeling of verapamil in renovascular hypertension</title><source>ScienceDirect Journals</source><creator>Bertera, Facundo M. ; Mayer, Marcos A. ; Opezzo, Javier A.W. ; Taira, Carlos A. ; Höcht, Christian</creator><creatorcontrib>Bertera, Facundo M. ; Mayer, Marcos A. ; Opezzo, Javier A.W. ; Taira, Carlos A. ; Höcht, Christian</creatorcontrib><description>The aim of this work was to compare the suitability of different pharmacodynamic models for PK–PD modeling of verapamil cardiovascular effects in aortic coarctated rats (ACo), a model of renovascular hypertension. A “shunt” microdialysis probe was inserted in a carotid artery of anaesthetized sham-operated (SO) and ACo rats for determination of verapamil plasma concentrations and their effects on blood pressure and heart rate after intravenous application (1 and 3 mg kg − 1 ). Correlation between verapamil plasma levels and their cardiovascular effects was established by fitting data to a linear, and a conventional and modified E max model. No differences in verapamil volume of distribution were observed between experimental groups. Whilst clearance increased with dose in SO rats, no differences were found in verapamil clearance in ACo comparing both dose levels. A good correlation between verapamil plasma unbound concentrations and their hypotensive and chronotropic effects was found in both experimental groups using the tested PK–PD models. Although all pharmacodynamic models allowed a precise estimation of verapamil PK–PD parameters, linear and E max model did not permit an accurate PK–PD parameter estimation for the hypotensive and chronotropic effect, respectively. Conversely, the modified E max model allows both a precise and accurate estimation of PK–PD parameters for verapamil effects. Although, absolute verapamil blood pressure lowering effect was greater in ACo rats compared with SO rats, no differences were found in verapamil PK–PD parameters estimated for the hypotensive response. Side-by-side comparison of the tested pharmacodynamic models showed that accuracy of PK–PD parameters estimation by using the linear and classical E max model depends on the magnitude of concentration–effect curve covered in the study. Conversely, the modified E max model allowed both a precise and accurate estimation of PK–PD parameters, suggesting that the modified E max pharmacodynamic model is the most suitable for verapamil PK–PD modeling.</description><identifier>ISSN: 1056-8719</identifier><identifier>EISSN: 1873-488X</identifier><identifier>DOI: 10.1016/j.vascn.2008.03.002</identifier><identifier>PMID: 18442930</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Aorta - surgery ; Aortic coarctation ; Aortic Coarctation - complications ; Aortic Coarctation - surgery ; Blood Pressure - drug effects ; Calcium Channel Blockers - pharmacokinetics ; Chronotropic effect ; Dose-Response Relationship, Drug ; Heart Rate - drug effects ; Hypertension, Renovascular - etiology ; Hypertension, Renovascular - metabolism ; Hypertension, Renovascular - physiopathology ; Hypotensive effect ; Injections, Intravenous ; Male ; Microdialysis ; Models, Biological ; Pharmacokinetic–pharmacodynamic modeling ; Plasma pharmacokinetics ; Rats ; Rats, Wistar ; Reproducibility of Results ; Verapamil ; Verapamil - pharmacokinetics</subject><ispartof>Journal of pharmacological and toxicological methods, 2008-05, Vol.57 (3), p.212-219</ispartof><rights>2008 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3482-1a15a7e84237bd45745e3e360d95cbc8c23ccb4a67ed7246a91e9d393298c4aa3</citedby><cites>FETCH-LOGICAL-c3482-1a15a7e84237bd45745e3e360d95cbc8c23ccb4a67ed7246a91e9d393298c4aa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18442930$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bertera, Facundo M.</creatorcontrib><creatorcontrib>Mayer, Marcos A.</creatorcontrib><creatorcontrib>Opezzo, Javier A.W.</creatorcontrib><creatorcontrib>Taira, Carlos A.</creatorcontrib><creatorcontrib>Höcht, Christian</creatorcontrib><title>Comparison of different pharmacodynamic models for PK–PD modeling of verapamil in renovascular hypertension</title><title>Journal of pharmacological and toxicological methods</title><addtitle>J Pharmacol Toxicol Methods</addtitle><description>The aim of this work was to compare the suitability of different pharmacodynamic models for PK–PD modeling of verapamil cardiovascular effects in aortic coarctated rats (ACo), a model of renovascular hypertension. A “shunt” microdialysis probe was inserted in a carotid artery of anaesthetized sham-operated (SO) and ACo rats for determination of verapamil plasma concentrations and their effects on blood pressure and heart rate after intravenous application (1 and 3 mg kg − 1 ). Correlation between verapamil plasma levels and their cardiovascular effects was established by fitting data to a linear, and a conventional and modified E max model. No differences in verapamil volume of distribution were observed between experimental groups. Whilst clearance increased with dose in SO rats, no differences were found in verapamil clearance in ACo comparing both dose levels. A good correlation between verapamil plasma unbound concentrations and their hypotensive and chronotropic effects was found in both experimental groups using the tested PK–PD models. Although all pharmacodynamic models allowed a precise estimation of verapamil PK–PD parameters, linear and E max model did not permit an accurate PK–PD parameter estimation for the hypotensive and chronotropic effect, respectively. Conversely, the modified E max model allows both a precise and accurate estimation of PK–PD parameters for verapamil effects. Although, absolute verapamil blood pressure lowering effect was greater in ACo rats compared with SO rats, no differences were found in verapamil PK–PD parameters estimated for the hypotensive response. Side-by-side comparison of the tested pharmacodynamic models showed that accuracy of PK–PD parameters estimation by using the linear and classical E max model depends on the magnitude of concentration–effect curve covered in the study. Conversely, the modified E max model allowed both a precise and accurate estimation of PK–PD parameters, suggesting that the modified E max pharmacodynamic model is the most suitable for verapamil PK–PD modeling.</description><subject>Animals</subject><subject>Aorta - surgery</subject><subject>Aortic coarctation</subject><subject>Aortic Coarctation - complications</subject><subject>Aortic Coarctation - surgery</subject><subject>Blood Pressure - drug effects</subject><subject>Calcium Channel Blockers - pharmacokinetics</subject><subject>Chronotropic effect</subject><subject>Dose-Response Relationship, Drug</subject><subject>Heart Rate - drug effects</subject><subject>Hypertension, Renovascular - etiology</subject><subject>Hypertension, Renovascular - metabolism</subject><subject>Hypertension, Renovascular - physiopathology</subject><subject>Hypotensive effect</subject><subject>Injections, Intravenous</subject><subject>Male</subject><subject>Microdialysis</subject><subject>Models, Biological</subject><subject>Pharmacokinetic–pharmacodynamic modeling</subject><subject>Plasma pharmacokinetics</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Reproducibility of Results</subject><subject>Verapamil</subject><subject>Verapamil - pharmacokinetics</subject><issn>1056-8719</issn><issn>1873-488X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNqFkU1uFDEQha0IRH7ICSIhr9h1U_7pbnuRBRpIQEQiC5Cyszx2NfGo227smZFmxx24ISdJDzNSdrCqUul7r0r1CLliUDNg7btVvbXFxZoDqBpEDcBPyBlTnaikUg8v5h6atlId06fkvJQVAAjN5CtyypSUXAs4I-MijZPNoaRIU0996HvMGNd0erR5tC75XbRjcHRMHodC-5Tp_Zc_v37ffziMQvyxF24x22kGBxoinQ3S_rbNYDN93E2Y1xhLSPE1ednboeDlsV6Q7zcfvy0-VXdfbz8v3t9VTkjFK2ZZYztUkotu6WXTyQYFiha8btzSKceFc0tp2w59x2VrNUPthRZcKyetFRfk7cF3yunnBsvajKE4HAYbMW2K6VgruOLyvyDTLWiQYgbFAXQ5lZKxN1MOo807w8Ds4zAr8zcOs4_DgDBzHLPqzdF-sxzRP2uO_5-B6wMw_xa3AbMpLmB06ENGtzY-hX8ueAKWip8w</recordid><startdate>200805</startdate><enddate>200805</enddate><creator>Bertera, Facundo M.</creator><creator>Mayer, Marcos A.</creator><creator>Opezzo, Javier A.W.</creator><creator>Taira, Carlos A.</creator><creator>Höcht, Christian</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>200805</creationdate><title>Comparison of different pharmacodynamic models for PK–PD modeling of verapamil in renovascular hypertension</title><author>Bertera, Facundo M. ; Mayer, Marcos A. ; Opezzo, Javier A.W. ; Taira, Carlos A. ; Höcht, Christian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3482-1a15a7e84237bd45745e3e360d95cbc8c23ccb4a67ed7246a91e9d393298c4aa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Animals</topic><topic>Aorta - surgery</topic><topic>Aortic coarctation</topic><topic>Aortic Coarctation - complications</topic><topic>Aortic Coarctation - surgery</topic><topic>Blood Pressure - drug effects</topic><topic>Calcium Channel Blockers - pharmacokinetics</topic><topic>Chronotropic effect</topic><topic>Dose-Response Relationship, Drug</topic><topic>Heart Rate - drug effects</topic><topic>Hypertension, Renovascular - etiology</topic><topic>Hypertension, Renovascular - metabolism</topic><topic>Hypertension, Renovascular - physiopathology</topic><topic>Hypotensive effect</topic><topic>Injections, Intravenous</topic><topic>Male</topic><topic>Microdialysis</topic><topic>Models, Biological</topic><topic>Pharmacokinetic–pharmacodynamic modeling</topic><topic>Plasma pharmacokinetics</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Reproducibility of Results</topic><topic>Verapamil</topic><topic>Verapamil - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bertera, Facundo M.</creatorcontrib><creatorcontrib>Mayer, Marcos A.</creatorcontrib><creatorcontrib>Opezzo, Javier A.W.</creatorcontrib><creatorcontrib>Taira, Carlos A.</creatorcontrib><creatorcontrib>Höcht, Christian</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmacological and toxicological methods</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bertera, Facundo M.</au><au>Mayer, Marcos A.</au><au>Opezzo, Javier A.W.</au><au>Taira, Carlos A.</au><au>Höcht, Christian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of different pharmacodynamic models for PK–PD modeling of verapamil in renovascular hypertension</atitle><jtitle>Journal of pharmacological and toxicological methods</jtitle><addtitle>J Pharmacol Toxicol Methods</addtitle><date>2008-05</date><risdate>2008</risdate><volume>57</volume><issue>3</issue><spage>212</spage><epage>219</epage><pages>212-219</pages><issn>1056-8719</issn><eissn>1873-488X</eissn><abstract>The aim of this work was to compare the suitability of different pharmacodynamic models for PK–PD modeling of verapamil cardiovascular effects in aortic coarctated rats (ACo), a model of renovascular hypertension. A “shunt” microdialysis probe was inserted in a carotid artery of anaesthetized sham-operated (SO) and ACo rats for determination of verapamil plasma concentrations and their effects on blood pressure and heart rate after intravenous application (1 and 3 mg kg − 1 ). Correlation between verapamil plasma levels and their cardiovascular effects was established by fitting data to a linear, and a conventional and modified E max model. No differences in verapamil volume of distribution were observed between experimental groups. Whilst clearance increased with dose in SO rats, no differences were found in verapamil clearance in ACo comparing both dose levels. A good correlation between verapamil plasma unbound concentrations and their hypotensive and chronotropic effects was found in both experimental groups using the tested PK–PD models. Although all pharmacodynamic models allowed a precise estimation of verapamil PK–PD parameters, linear and E max model did not permit an accurate PK–PD parameter estimation for the hypotensive and chronotropic effect, respectively. Conversely, the modified E max model allows both a precise and accurate estimation of PK–PD parameters for verapamil effects. Although, absolute verapamil blood pressure lowering effect was greater in ACo rats compared with SO rats, no differences were found in verapamil PK–PD parameters estimated for the hypotensive response. Side-by-side comparison of the tested pharmacodynamic models showed that accuracy of PK–PD parameters estimation by using the linear and classical E max model depends on the magnitude of concentration–effect curve covered in the study. Conversely, the modified E max model allowed both a precise and accurate estimation of PK–PD parameters, suggesting that the modified E max pharmacodynamic model is the most suitable for verapamil PK–PD modeling.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>18442930</pmid><doi>10.1016/j.vascn.2008.03.002</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1056-8719
ispartof Journal of pharmacological and toxicological methods, 2008-05, Vol.57 (3), p.212-219
issn 1056-8719
1873-488X
language eng
recordid cdi_proquest_miscellaneous_71632824
source ScienceDirect Journals
subjects Animals
Aorta - surgery
Aortic coarctation
Aortic Coarctation - complications
Aortic Coarctation - surgery
Blood Pressure - drug effects
Calcium Channel Blockers - pharmacokinetics
Chronotropic effect
Dose-Response Relationship, Drug
Heart Rate - drug effects
Hypertension, Renovascular - etiology
Hypertension, Renovascular - metabolism
Hypertension, Renovascular - physiopathology
Hypotensive effect
Injections, Intravenous
Male
Microdialysis
Models, Biological
Pharmacokinetic–pharmacodynamic modeling
Plasma pharmacokinetics
Rats
Rats, Wistar
Reproducibility of Results
Verapamil
Verapamil - pharmacokinetics
title Comparison of different pharmacodynamic models for PK–PD modeling of verapamil in renovascular hypertension
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T12%3A38%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20different%20pharmacodynamic%20models%20for%20PK%E2%80%93PD%20modeling%20of%20verapamil%20in%20renovascular%20hypertension&rft.jtitle=Journal%20of%20pharmacological%20and%20toxicological%20methods&rft.au=Bertera,%20Facundo%20M.&rft.date=2008-05&rft.volume=57&rft.issue=3&rft.spage=212&rft.epage=219&rft.pages=212-219&rft.issn=1056-8719&rft.eissn=1873-488X&rft_id=info:doi/10.1016/j.vascn.2008.03.002&rft_dat=%3Cproquest_cross%3E19609043%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3482-1a15a7e84237bd45745e3e360d95cbc8c23ccb4a67ed7246a91e9d393298c4aa3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=19609043&rft_id=info:pmid/18442930&rfr_iscdi=true